You have 9 free searches left this month | for more free features.

C225

Showing 1 - 25 of 2,572

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Colon Cancer, Colorectal Cancer Trial in Houston (MRTX849, Irinotecan, Cetuximab)

Not yet recruiting
  • Colon Cancer
  • Colorectal Cancer
  • Houston, Texas
    M D Anderson Cancer Center
Feb 1, 2023

Metastatic Colorectal Adenocarcinoma, Refractory Colorectal Adenocarcinoma, Stage IV Colorectal Cancer AJCC v8 Trial (drug,

Not yet recruiting
  • Metastatic Colorectal Adenocarcinoma
  • +2 more
  • BET Bromodomain Inhibitor ZEN-3694
  • +6 more
  • (no location specified)
Oct 25, 2023

Metastatic Colorectal Cancer Trial (Cetuximab + Envafolimab + mFOLFOXIRI, Cetuximab + mFOLFOX6/FOLFIRI)

Not yet recruiting
  • Metastatic Colorectal Cancer
  • Cetuximab + Envafolimab + mFOLFOXIRI
  • Cetuximab + mFOLFOX6/FOLFIRI
  • (no location specified)
Jul 24, 2023

Recurrent Colorectal Carcinoma, Stage IVA Colorectal Cancer, Stage IVB Colorectal Cancer Trial in Buffalo, Cleveland (Cetuximab,

Completed
  • Recurrent Colorectal Carcinoma
  • +2 more
  • Cetuximab
  • +2 more
  • Buffalo, New York
  • +1 more
Sep 29, 2022

Chordoma, Metastatic Chordoma, Unresectable Chordoma Trial in Houston (Cetuximab, Questionnaire Administration)

Recruiting
  • Chordoma
  • +2 more
  • Cetuximab
  • Questionnaire Administration
  • Houston, Texas
    M D Anderson Cancer Center
Jun 1, 2022

Colon Cancer, Resected Stage Trial in Houston (Cetuximab, CB-NK-TGF-βR2-/NR3C1, Fludarabine phosphate)

Recruiting
  • Colon Cancer
  • Resected Stage
  • Houston, Texas
    M D Anderson Cancer Center
Jul 23, 2022

Metastatic Colorectal Carcinoma, Stage IV Colorectal Cancer AJCC v8, Stage IVA Colorectal Cancer AJCC v8 Trial in Houston

Active, not recruiting
  • Metastatic Colorectal Carcinoma
  • +4 more
  • Cetuximab
  • +3 more
  • Houston, Texas
    M D Anderson Cancer Center
Aug 4, 2022

BRAF NP_004324.2:p.V600X, KRAS wt Allele, Metastatic Malignant Solid Tumor Trial in Houston (biological, drug, other)

Active, not recruiting
  • BRAF NP_004324.2:p.V600X
  • +6 more
  • Cetuximab
  • +4 more
  • Houston, Texas
    M D Anderson Cancer Center
Sep 22, 2022

Active, not recruiting
  • Stage III Hypopharyngeal Squamous Cell Carcinoma AJCC v7
  • +8 more
  • Cetuximab
  • +3 more
  • Pittsburgh, Pennsylvania
    University of Pittsburgh Cancer Institute (UPCI)
Jan 26, 2023

Metastatic Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma, Unresectable Head and Neck

Active, not recruiting
  • Metastatic Head and Neck Squamous Cell Carcinoma
  • +2 more
  • Cetuximab
  • +2 more
  • Washington, District of Columbia
  • +1 more
Mar 25, 2022

Colon Adenocarcinoma, Microsatellite Stable Colon Carcinoma, Stage IIB Colon Cancer AJCC v8 Trial (drug, biological, procedure,

Not yet recruiting
  • Colon Adenocarcinoma
  • +4 more
  • (no location specified)
Jan 24, 2023

Advanced Cancers Trial in Houston (Regorafenib, Cetuximab, Questionnaire)

Completed
  • Advanced Cancers
  • Houston, Texas
    University of Texas MD Anderson Cancer Center
Mar 31, 2021

BRAF V600E Negative, KRAS Gene Mutation Negative, Locally Advanced Unresectable Colorectal Adenocarcinoma Trial in United States

Recruiting
  • BRAF V600E Negative
  • +12 more
  • Cetuximab
  • +3 more
  • Scottsdale, Arizona
  • +15 more
Aug 23, 2022

NASH With Fibrosis Trial ([14C]-rencofilstat 225mg)

Not yet recruiting
  • NASH With Fibrosis
  • [14C]-rencofilstat 225mg
  • (no location specified)
Feb 21, 2023

Metastatic Colorectal Carcinoma, Metastatic Malignant Tumor in the Liver, Stage IV Colorectal Cancer AJCC v8 Trial (biological,

Not yet recruiting
  • Metastatic Colorectal Carcinoma
  • +3 more
  • Bevacizumab
  • +11 more
  • (no location specified)
May 9, 2023

Stage III Squamous Cell Carcinoma of the Hypopharynx, Stage III Squamous Cell Carcinoma of the Larynx, Stage III Squamous Cell

Terminated
  • Stage III Squamous Cell Carcinoma of the Hypopharynx
  • +11 more
  • cetuximab
  • +3 more
  • Newark, New Jersey
    New Jersey Medical School
Apr 19, 2021

Metastatic Colorectal Cancer Trial in Philadelphia (drug, biological, genetic, other)

Terminated
  • Metastatic Colorectal Cancer
  • Philadelphia, Pennsylvania
    Fox Chase Cancer Center
Feb 22, 2021

Advanced Malignant Tumor, Castleman Disease, Digestive System Carcinoma Trial in Houston (biological, other, drug)

Active, not recruiting
  • Advanced Malignant Neoplasm
  • +38 more
  • Bevacizumab
  • +5 more
  • Houston, Texas
    M D Anderson Cancer Center
Jul 18, 2022

Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With

Completed
  • Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma
  • +35 more
  • PI3K inhibitor BKM120
  • cetuximab
  • Chicago, Illinois
    University of Chicago Comprehensive Cancer Center
Sep 14, 2021

Metastatic Colon Adenocarcinoma, Metastatic Colorectal Carcinoma, Metastatic Rectal Adenocarcinoma Trial in Houston

Recruiting
  • Metastatic Colon Adenocarcinoma
  • +30 more
  • Houston, Texas
    M D Anderson Cancer Center
Jan 24, 2022

Glioblastoma Trial in Aarau, Basel (C225-ILs-dox)

Completed
  • Glioblastoma
  • Aarau, Switzerland
  • +1 more
Dec 7, 2020

Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage IV HPV-Mediated (p16-Positive)

Recruiting
  • Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
  • +4 more
  • Cetuximab
  • +4 more
  • Los Angeles, California
    UCLA / Jonsson Comprehensive Cancer Center
Oct 4, 2021

Carcinoma, Squamous Cell Trial in Syracuse (drug, biological, radiation)

Completed
  • Carcinoma, Squamous Cell
  • paclitaxel poliglumex
  • +2 more
  • Syracuse, New York
    SUNY Upstate Medical University
Oct 29, 2021

Advanced Solid Tumours, Actinium-225, Antineoplastic Agents Trial in Australia, Canada, United States ([111In]-FPI-1547

Recruiting
  • Advanced Solid Tumours
  • +4 more
  • [111In]-FPI-1547 Injection
  • +3 more
  • Duarte, California
  • +12 more
Mar 2, 2022

Colorectal Adenocarcinoma, RAS Wild Type, Stage IV Colorectal Cancer AJCC v7 Trial in United States (biological, drug, other)

Completed
  • Colorectal Adenocarcinoma
  • +4 more
  • Bevacizumab
  • +4 more
  • Scottsdale, Arizona
  • +12 more
Jan 27, 2022